RxDoctor Payments Data

Ashlee Dirado

Medical · Erie, PANPI 1174939730

Payments from drug & device makers

$2,297in general payments, 2019–2025

Across 76 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Medtronic$171
  • Boston Scientific$137
  • 180 Medical, Inc.$121
  • Progenics Pharmaceuticals, Inc.$109
  • Procept Biorobotics Corporation$105
  • plus $367 from 7 others

What the payments were for

  • Food & beverage$2,13293%
  • Education$1657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,297 in reported general payments places this provider in the 80th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$16,532
Medicare patients
147
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron49$34,529
GemtesaVibegron39$26,405
Tamsulosin Hcl244$3,366
Tolterodine Tartrate ErTolterodine Tartrate30$2,128
Estradiol27$1,871
Solifenacin Succinate16$1,065
Finasteride65$1,052
Methenamine Hippurate20$520
Cefdinir43$369
Allopurinol25$222
Ciprofloxacin Hcl59$201
Alfuzosin Hcl ErAlfuzosin Hcl16$191
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$182
Cephalexin36$148
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim44$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,288$34,52949 claims
Sumitomo Pharma America, Inc.Gemtesa$28$26,40539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →